63 research outputs found
Counterregulatory Hormone Responses During Graded Hyperinsulinemic Euglycemia in Conscious Rats
Serum triiodothyronine levels and inflammatory cytokine production capacity
Increasing evidence suggests that pro-inflammatory cytokines are at play in lowering peripheral thyroid hormone levels during critical illness. Conversely, thyroid hormones have been suggested to enhance production of inflammatory cytokines. In view of these considerations, we hypothesized a mutual association between triiodothyronine and pro-inflammatory cytokines. Therefore we evaluated the relation between both circulating and induced inflammatory markers and serum thyroid function parameters in the Leiden 85-plus Study. We found that higher circulating levels of inflammatory markers were associated with lower levels of free serum triiodothyronine. In turn, higher serum free triiodothyronine levels were related to higher production capacity of pro-inflammatory cytokines after stimulation with lipopolysaccharide. By combining in vivo and ex vivo data, we were able to demonstrate for the first time the existence of a potential feedback mechanism between thyroid function and immune production capacity. We conclude that maintenance of normal thyroid function might be important for a preserved immune response in elderly human populations
Adverse environmental conditions influence age-related innate immune responsiveness
BACKGROUND-: The innate immune system plays an important role in the recognition and induction of protective responses against infectious pathogens, whilst there is increasing evidence for a role in mediating chronic inflammatory diseases at older age. Despite indications that environmental conditions can influence the senescence process of the adaptive immune system, it is not known whether the same holds true for the innate immune system. Therefore we studied whether age-related innate immune responses are similar or differ between populations living under very diverse environmental conditions. METHODS-: We compared cross-sectional age-related changes in ex vivo innate cytokine responses in a population living under affluent conditions in the Netherlands (age 20–68 years old, n = 304) and a population living under adverse environmental conditions in Ghana (age 23–95 years old, n = 562). RESULTS-: We found a significant decrease in LPS-induced Interleukin (IL)-10 and Tumor Necrosis Factor (TNF) production with age in the Dutch population. In Ghana a similar age-related decline in IL-10 responses to LPS, as well as to zymosan, or LPS plus zymosan, was observed. TNF production, however, did not show an age-associated decline, but increased significantly with age in response to co-stimulation with LPS and zymosan. CONCLUSION-: We conclude that the decline in innate cytokine responses is an intrinsic ageing phenomenon, while pathogen exposure and/or selective survival drive pro-inflammatory responses under adverse living conditions
A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation
We assessed the effectiveness and safety of 3 yr combined GH and GnRH
agonist (GnRHa) treatment in a randomized controlled study in children
with idiopathic short stature (ISS) or intrauterine growth retardation
(IUGR). Gonadal suppression, GH reserve, and adrenal development were
assessed by hormone measurements in both treated children and controls
during the study period. Thirty-six short children, 24 girls (16 ISS/8
IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less
in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to
treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa
(triptorelin, 3.75 mg/28 days) or no treatment (n = 18). At the start of
the study mean (SD) age was 11.4 (0.56) or 12.2 (1.12) yr whereas bone age
was 10.7 (0.87) or 10.9 (0.63) yrs in girls and boys, respectively. During
3 yr of study height SD score for chronological age did not change in both
treated children and controls, whereas a decreased rate of bone maturation
after treatment was observed [mean (SD) 0.55 (0.21) 'yr'/yr vs. 1.15
(0.37) 'yr'/yr in controls, P < 0.001, girls and boys together]. Height SD
score for bone age and predicted adult height increased significantly
after 3 yr of treatment; compared with controls the predicted adult height
gain was 8.0 cm in girls and 10.4 cm in boys. Furthermore, the ratio
between sitting height/height SD score decreased significantly in treated
children, whereas body mass index was not influenced by treatment. Puberty
was effectively arrested in the treated children, as was confirmed by
physical examination and prepubertal testosterone and estradiol levels.
GH-dependent hormones including serum insulin-like growth factor I and II,
carboxy terminal propeptide of type I collagen, amino terminal propeptide
of type III collagen, alkaline phosphatase, and osteocalcin were not
different between treated children and controls during the study period.
Thus, a GH dose of 4 IU/m(2) seems adequate for stabilization of the GH
reserve and growth in these GnRHa-treated children. We conclude that 3 yr
treatment with GnRHa was effective in suppressing pubertal development and
skeletal maturation, whereas the addition of GH preserved growth velocity
during treatment. This resulted in a considerable gain in predicted adult
height, without demonstrable side effects. Final height results will
provide the definite answer on the effectiveness of this combined
treatment
Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
<p>Background: Venous thromboembolic events (VTE), including deep venous thrombosis and pulmonary embolism, are common in older age. It has been suggested that statins might reduce the risk of VTE however positive results from studies of middle aged subjects may not be generalisable to elderly people. We aimed to determine the effect of pravastatin on incident VTE in older people; we also studied the impact of clinical and plasma risk variables.</p>
<p>Methods: This study was an analysis of incident VTE using data from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), a randomized, double-blind, placebo-controlled trial of pravastatin in men and women aged 70-82. Mean follow-up was 3.2 years. Risk for VTE was examined in non-warfarin treated pravastatin (n = 2834) and placebo (n = 2865) patients using a Cox's proportional hazard model, and the impact of other risk factors assessed in a multivariate forward stepwise regression analysis. Baseline clinical characteristics, blood biochemistry and hematology variables, plasma levels of lipids and lipoproteins, and plasma markers of inflammation and adiposity were compared. Plasma markers of thrombosis and hemostasis were assessed in a nested case (n = 48) control (n = 93) study where the cohort was those participants, not on warfarin, for whom data were available.</p>
<p>Results: There were 28 definite cases (1.0%) of incident VTE in the pravastatin group recipients and 20 cases (0.70%) in placebo recipients. Pravastatin did not reduce VTE in PROSPER compared to placebo [unadjusted hazard ratio (95% confidence interval) 1.42 (0.80, 2.52) p = 0.23]. Higher body mass index (BMI) [1.09 (1.02, 1.15) p = 0.0075], country [Scotland vs Netherlands 4.26 (1.00, 18.21) p = 0.050 and Ireland vs Netherlands 6.16 (1.46, 26.00) p = 0.013], lower systolic blood pressure [1.35 (1.03, 1.75) p = 0.027] and lower baseline Mini Mental State Examination (MMSE) score [1.19 (1.01, 1.41) p = 0.034] were associated with an increased risk of VTE, however only BMI, country and systolic blood pressure remained significant on multivariate analysis. In a nested case control study of definite VTE, plasma Factor VIII levels were associated with VTE [1.52 (1.01, 2.28), p = 0.044]. However no other measure of thrombosis and haemostasis was associated with increased risk of VTE.</p>
<p>Conclusions: Pravastatin does not prevent VTE in elderly people at risk of vascular disease. Blood markers of haemostasis and inflammation are not strongly predictive of VTE in older age however BMI, country and lower systolic blood pressure are independently associated with VTE risk.</p>
Selection for Genetic Variation Inducing Pro-Inflammatory Responses under Adverse Environmental Conditions in a Ghanaian Population
BACKGROUND:Chronic inflammation is involved in the pathogenesis of chronic age-associated, degenerative diseases. Pro-inflammatory host responses that are deleterious later in life may originate from evolutionary selection for genetic variation mediating resistance to infectious diseases under adverse environmental conditions. METHODOLOGY/PRINCIPAL FINDINGS:In the Upper-East region of Ghana where infection has remained the leading cause of death, we studied the effect on survival of genetic variations at the IL10 gene locus that have been associated with chronic diseases. Here we show that an IL10 haplotype that associated with a pro-inflammatory innate immune response, characterised by low IL-10 (p = 0.028) and high TNF-alpha levels (p = 1.39 x 10(-3)), was enriched among Ghanaian elders (p = 2.46 x 10(-6)). Furthermore, in an environment where the source of drinking water (wells/rivers vs. boreholes) influences mortality risks (HR 1.28, 95% CI [1.09-1.50]), we observed that carriers of the pro-inflammatory haplotype have a survival advantage when drinking from wells/rivers but a disadvantage when drinking from boreholes (p(interaction) = 0.013). Resequencing the IL10 gene region did not uncover any additional common variants in the pro-inflammatory haplotype to those SNPs that were initially genotyped. CONCLUSIONS/SIGNIFICANCE:Altogether, these data lend strong arguments for the selection of pro-inflammatory host responses to overcome fatal infection and promote survival in adverse environments
- …